Trial Profile
Study of a biosimilar infliximab switch in patients with inflammatory bowel disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2018
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Inflammatory bowel diseases
- Focus Adverse reactions; Therapeutic Use
- 09 Nov 2018 New trial record
- 10 Oct 2018 Results presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2018